AEM vs GEVO

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

GEVO exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial instability. While the company shows explosive year-over-year revenue growth of 695.60% and recent earnings beats, these are overshadowed by negative profit margins and a complete lack of positive cash flow. The disconnect between bullish analyst targets ($5.50) and aggressive insider selling (15 sell transactions, 0 buys) suggests a high-risk speculative profile. The technical trend is currently bearish, and the lack of a Graham Number reflects the company's inability to generate earnings.